大洋生物：实控人的一致行动人拟合计减持不超约84万股

Group 1 - The actual controllers of Dayang Biotechnology plan to reduce their shareholding by a total of approximately 840,000 shares, not exceeding 1% of the company's total share capital, within three months after the disclosure of the share reduction plan [1] - As of the announcement date, the shareholding details are as follows: Mr. Hao Bingyan holds approximately 1.34% of the total shares, Mr. Qian Jianchun holds 0.92%, Mr. Chen Shouliang holds 0.24%, and Ms. Zhao Yumei holds 0.06% [1] - For the first half of 2025, Dayang Biotechnology's revenue composition is 95.72% from the chemical industry and 4.28% from other sources [1] Group 2 - Dayang Biotechnology has a market capitalization of 2.7 billion yuan [1]